What’s Really at Stake When Trade Policy Shifts? For Life Sciences Companies, Everything

Not just the cost of goods, but timelines, clinical trial viability, supplier continuity, and the assumptions your entire strategy is built on. While tariffs present challenges, they also offer opportunities for innovation and strategic growth within the life sciences sector. By staying informed and prepared, companies can effectively mitigate risks and capitalise on emerging industry trends.

This article captures key takeaways from NSF’s recent 30-minute live round table session, where experts in pharma, clinical, medical devices, and government affairs broke down how global trade shifts are impacting the life sciences industry—and what forward-thinking companies are doing in response.

• Why some companies are reclassifying materials and insourcing operations to reduce exposure
• How new supply models are emerging across clinical trials and device manufacturing
• What risks industry leaders are watching next, including national security reviews and reciprocal tariff threats
• Tactical moves that pharma, medtech, clinical and biotech teams are using now to protect margin and maintain continuity

The most resilient companies aren’t waiting to see what happens. They’re already adjusting. Here’s how.